Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Number Of EGDC Users Surge
Over 2,600 dental care professionals have created accounts on the General Dental Council"s site, eGDC, since its re-launch in April this year. This brings the total number of dental professionals who are using the site, first launched last November, to over 5,200.

CSL Biotherapies Starts Shipment Of Seasonal Influenza Vaccine For The 2009-2010 Flu Season
CSL Biotherapies, a subsidiary of one of the world"s leading manufacturers of thimerosal-free seasonal influenza vaccine, announced that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes.
News of the day
Discovery Of Possible Drug Target For One Of The Most Aggressive Breast Cancers
Van Andel Research Institute (VARI) investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer. Currently, patients with these cancers have few treatment options.
Nutrition

Hebrew University Research Leads To Advanced Trials Of New Cancer Treatment

Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells. The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year"s Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting. Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells. Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases. The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods. Prof. Hochberg"s research was patented by Yissum Research Development Company of the Hebrew University. In 2005 Yissum established BioCancell Inc., to which it licensed the technology. The company is now traded in the Tel Aviv stock exchange (TASE). BioCancell"s leading product, BC-819, has demonstrated efficacy in clinical trials (now in an advanced stage) in Israel and the US for the treatment of human bladder, pancreatic and ovarian cancers. Jerry Barach The Hebrew University of Jerusalem


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009